Richard Barry - Net Worth and Insider Trading
Richard Barry Net Worth
The estimated net worth of Richard Barry is at least $418 Million dollars as of 2024-05-05. Richard Barry is the Director of Sarepta Therapeutics Inc and owns about 3,079,842 shares of Sarepta Therapeutics Inc (SRPT) stock worth over $412 Million. Richard Barry is the Director of Cassava Sciences Inc and owns about 293,477 shares of Cassava Sciences Inc (SAVA) stock worth over $6 Million. Richard Barry is also the 10% Owner of MabVax Therapeutics Holdings Inc and owns about 1,373 shares of MabVax Therapeutics Holdings Inc (MBVXQ) stock worth over $32. Details can be seen in Richard Barry's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Richard Barry has not made any transactions after 2023-11-03 and currently still holds the listed stock(s).
Transaction Summary of Richard Barry
Richard Barry Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Richard Barry owns 4 companies in total, including Sarepta Therapeutics Inc (SRPT) , MiMedx Group Inc (MDXG) , and MabVax Therapeutics Holdings Inc (MBVXQ) among others .
Click here to see the complete history of Richard Barry’s form 4 insider trades.
Insider Ownership Summary of Richard Barry
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc | 2023-11-03 | director |
| MDXG | MiMedx Group Inc | 2019-06-19 | director |
| MBVXQ | MabVax Therapeutics Holdings Inc | 2012-12-17 | 10 percent owner |
 | | 2023-08-22 | director |
Richard Barry Latest Holdings Summary
Richard Barry currently owns a total of 3 stocks. Among these stocks, Richard Barry owns 3,079,842 shares of Sarepta Therapeutics Inc (SRPT) as of November 3, 2023, with a value of $412 Million and a weighting of 98.45%. Richard Barry owns 293,477 shares of Cassava Sciences Inc (SAVA) as of August 22, 2023, with a value of $6 Million and a weighting of 1.55%. Richard Barry also owns 1,373 shares of MabVax Therapeutics Holdings Inc (MBVXQ) as of December 17, 2012, with a value of $32 and a weighting of 0%.
Latest Holdings of Richard Barry
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc | 2023-11-03 | 3,079,842 | 133.66 | 411,651,682 |
| SAVA | Cassava Sciences Inc | 2023-08-22 | 293,477 | 22.05 | 6,471,168 |
| MBVXQ | MabVax Therapeutics Holdings Inc | 2012-12-17 | 1,373 | 0.02 | 32 |
Holding Weightings of Richard Barry
Richard Barry Form 4 Trading Tracker
According to the SEC Form 4 filings, Richard Barry has made a total of 7 transactions in Sarepta Therapeutics Inc (SRPT) over the past 5 years, including 5 buys and 2 sells. The most-recent trade in Sarepta Therapeutics Inc is the acquisition of 50,000 shares on November 3, 2023, which cost Richard Barry around $4 Million.
According to the SEC Form 4 filings, Richard Barry has made a total of 3 transactions in Cassava Sciences Inc (SAVA) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cassava Sciences Inc is the acquisition of 18,477 shares on August 22, 2023, which cost Richard Barry around $308,012.
According to the SEC Form 4 filings, Richard Barry has made a total of 0 transactions in MabVax Therapeutics Holdings Inc (MBVXQ) over the past 5 years. The most-recent trade in MabVax Therapeutics Holdings Inc is the sale of 272 shares on December 17, 2012, which brought Richard Barry around $90,005.
Insider Trading History of Richard Barry
- 1
Richard Barry Trading Performance
GuruFocus tracks the stock performance after each of Richard Barry's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Richard Barry is 14.99%. GuruFocus also compares Richard Barry's trading performance to market benchmark return within the same time period. The performance of stocks bought by Richard Barry within 3 months outperforms 5 times out of 9 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Richard Barry's insider trading performs compared to the benchmark.
Performance of Richard Barry
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 2.35 | | | | | |
| Relative Return to S&P 500(%) | 1.06 | | | | | |
Richard Barry Ownership Network
Richard Barry Owned Company Details
What does Sarepta Therapeutics Inc do?
Who are the key executives at Sarepta Therapeutics Inc?
Richard Barry is the director of Sarepta Therapeutics Inc. Other key executives at Sarepta Therapeutics Inc include Chief Tech Ops Officer Bilal Arif , Chief Financial Officer Ian Michael Estepan , and SVP & General Counsel Ryan Edward Brown .
Sarepta Therapeutics Inc (SRPT) Insider Trades Summary
Over the past 18 months, Richard Barry made 1 insider transaction in Sarepta Therapeutics Inc (SRPT) with a net purchase of 50,000. Other recent insider transactions involving Sarepta Therapeutics Inc (SRPT) include a net purchase of 68,532 shares made by Michael Andrew Chambers , a net sale of 30,000 shares made by Wigzell Hans Lennart Rudolf , and a net sale of 3,993 shares made by Stephen Mayo .
In summary, during the past 3 months, insiders sold 24,096 shares of Sarepta Therapeutics Inc (SRPT) in total and bought 0 shares, with a net sale of 24,096 shares. During the past 18 months, 39,954 shares of Sarepta Therapeutics Inc (SRPT) were sold and 143,757 shares were bought by its insiders, resulting in a net purchase of 103,803 shares.
Sarepta Therapeutics Inc (SRPT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Sarepta Therapeutics Inc Insider Transactions
Richard Barry Mailing Address
Above is the net worth, insider trading, and ownership report for Richard Barry. You might contact Richard Barry via mailing address: 285 Margalita Drive, San Rafael Ca 94901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
